Floatz logo

Zoladex

Non-Small Cell Lung Cancer

Novartis PharmaceuticalsPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
59/ 100

Competitive context

175 Active assets in the Non-Small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Anamorelin
Helsinn Healthcare SA
Phase 3BB
Atezolizumab
National Cancer Institute (NCI)
Phase 4BB
Docetaxel
Genfleet Therapeutics (Shanghai) Inc.
Phase 4BB
ETOPOSIDE
Pfizer
Phase 3BB
ALECTINIB
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Phase 4BB

View all 50 →

Same molecule, other indications

Zoladex is also rated in:

HR+/HER2- Breast CancerDormant
BB
Indicative ·
71 / 100
View asset →
prostate neoplasmDormant
BB
Indicative ·
69 / 100
View asset →
prostate adenocarcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →